Drug intelligence / Profile preview

SKM-101

Development stage: Preclinical
Lead developer: Skymab Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SKM-101 is a preclinical-stage monoclonal antibody being developed by Skymab Biotherapeutics for the treatment of solid tumors. The therapeutic candidate is designed to target G-protein coupled receptor 1 (GPR1, also known as GPCR1), a cell-surface receptor that is overexpressed in various cancer types. By targeting GPR1, SKM-101 aims to inhibit tumor growth and progression, offering a potential targeted therapy for patients with solid tumors.

Other names: SKM101SKM-101SKM 101

Targets

GPR1

Beyond the preview

Go deeper on SKM-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKM-101.

Explore the full profile